Serum Adalimumab Concentration and Clinical Remission in Patients with Crohnʼs Disease
- 1 May 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 19 (6) , 1112-1122
Abstract
Background. Drug concentration monitoring may be useful to guide therapeutic adjustments for anti–tumor necrosis factor agents in Crohn's disease. The relationKeywords
This publication has 25 references indexed in Scilit:
- Assessing Response and Loss of Response to Biological Therapies in IBDAmerican Journal of Gastroenterology, 2011
- Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel DiseaseAmerican Journal of Gastroenterology, 2010
- Optimizing the Use of Tumour Necrosis Factor Inhibitors in Crohnʼs DiseaseDrugs, 2010
- Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodiesScandinavian Journal of Gastroenterology, 2009
- Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's DiseaseAmerican Journal of Gastroenterology, 2008
- Maintenance Therapy with Certolizumab Pegol for Crohn's DiseaseNew England Journal of Medicine, 2007
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Tumor necrosis factor: Biology and therapeutic inhibitorsGastroenterology, 2000
- Tumour necrosis factor and Crohn's disease.Gut, 1997